Voiant laajentaa kliinisten tutkimusten kuvantamispalveluita aineenvaihduntasairauksiin
Voiant laajentaa kuvantamispalveluitaan aineenvaihduntasairauksien ja lihavuuden tutkimukseen. Yritys tarjoaa perinteisiä painonhallintamittauksia syvempiä kuvausmenetelmiä.
Voiant, a clinical trial imaging services provider, announced on August 4, 2026, its expansion into research for obesity and metabolic diseases. The company aims to provide sponsors with advanced body composition and metabolic imaging endpoints, moving beyond traditional weight-loss metrics.
The Waltham, Massachusetts-based firm will focus on offering specialized imaging techniques to better understand disease progression and treatment efficacy in metabolic conditions. This move is expected to enhance the depth of data available in clinical trials for these complex diseases.
By incorporating advanced imaging, Voiant seeks to support pharmaceutical and biotechnology companies in their development of new therapies. The company's services are designed to offer more precise and quantitative data, potentially accelerating drug development timelines.
This expansion signifies Voiant's commitment to broadening its support for therapeutic areas. The company previously offered services across various other medical fields. The new focus area addresses a growing global health concern, with obesity and metabolic disorders affecting a significant portion of the population.